SEC Comment Letter 0000000000-23-012764 to IOVANCE BIOTHERAPEUTICS, INC. (IOVA) (CIK 0001425205) (IOVA)
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) (CIK 0001425205)
Date: Nov. 21, 2023 · CIK: 0001425205 · Accession: 0000000000-23-012764
AI Filing Summary & Sentiment
File numbers found in text: 001-36860
Letter
United States securities and exchange commission logo November 21, 2023 Frederick G. Vogt Interim Chief Executive Officer Iovance Biotherapeutics, Inc. 825 Industrial Road Suite 400 San Carlos , California Re:Iovance Biotherapeutics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2022 Filed February 28, 2023 File No. 001-36860 Dear Frederick G. Vogt: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
November 21, 2023
Frederick G. Vogt
Interim Chief Executive Officer
Iovance Biotherapeutics, Inc.
825 Industrial Road
Suite 400
San Carlos , California
Re:Iovance Biotherapeutics, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2022
Filed February 28, 2023
File No. 001-36860
Dear Frederick G. Vogt:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences